Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis

Part of Hypersensitivity, Immediate

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Allergic Bronchopulmonary Aspergillosis

5 trials tracked for Allergic Bronchopulmonary Aspergillosis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 234 citations.

5Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 1 Phase 1 1 Other / NA 1
  1. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Completed · 234 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Completed
  3. Phase 2 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Completed
  4. Phase 1 Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Completed
  5. N/A Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Allergic Bronchopulmonary Aspergillosis: what the trials found

Ibrexafungerp demonstrated varying rates of global response as determined by the Data Review Committee (DRC) across different cohorts. Response rates were reported at 142%, 69%, 22%, 131%, 59%, and 5% for general participants, while enrollment categories showed responses of 74%, 41%, 13%, 95%, 29%, and 10% 2. By disease category, the global response rates were 70%, 22%, 12%, 52%, 19%, and 4% 2.

Recent results — preliminary, needs further review

  • Dupilumab showed a statistically significant improvement in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) compared to placebo (p=0.0022) 3.
  • Inhaled voriconazole was evaluated in a Phase 1 study 4.

For the clinician treating this condition

  • Ibrexafungerp shows varying efficacy for global response depending on the specific cohort and disease category 2.
  • Dupilumab is associated with significant improvements in FEV1, though results are not yet corroborated 3.

AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of animal models for allergic fungal airway disease and asthma
Infectious Disease Sys. Review
Review of animal models for allergic fungal airway disease and asthma Animal models reveal how fungi trigger severe asthma
This narrative review examines animal models for allergic fungal airway disease, allergic bronchopulmonary aspergillosis, and asthma. The au…
New review shows spore-based animal models better mimic human allergic fungal airway disease, pointing to new treatment targets.
Frontiers May 28, 2026
Systematic review finds moderate to substantial concordance among fungal sIgE detection kits for asthma
Allergy & Immunology Sys. Review
Systematic review finds moderate to substantial concordance among fungal sIgE detection kits for asthma Review finds variation in tests for fungal allergy in asthma patients
A systematic review of 16 human studies evaluating 32 commercial fungal sIgE detection kits found moderate to substantial concordance with t…
Asthma fungal allergy tests often give different results because commercial kits use different methods and cut-off points, making it hard to…
Frontiers Apr 8, 2026

Research across Hypersensitivity, Immediate

Related studies from across the Hypersensitivity, Immediate family.

Allergic conjunctivitis pathogenesis and endotypes point toward precision therapy
Allergy & Immunology Sys. Review
Allergic conjunctivitis pathogenesis and endotypes point toward precision therapy New insights into allergic conjunctivitis could lead to personalized treatments
This narrative review explores pathophysiological and molecular mechanisms of allergic conjunctivitis, including local and systemic immune r…
A review reveals how genetic and immune factors drive allergic conjunctivitis, paving the way for tailored therapies.
Frontiers Jun 23, 2026
Astragali Radix metabolites show anti-inflammatory and immunomodulatory activities for allergic respiratory conditions
Drug Pipeline Sys. Review
Astragali Radix metabolites show anti-inflammatory and immunomodulatory activities for allergic respiratory conditions Astragali Radix metabolites show promise for allergic airway diseases
This narrative review examines the potential of Astragali Radix metabolites, including polysaccharides, saponins, and flavonoids, for allerg…
A review suggests Astragali Radix metabolites may help treat allergic asthma and related conditions through anti-inflammatory and immunomodu…
Frontiers Jun 3, 2026
Narrative review identifies emerging associations between gut microbiota and pediatric eye conditions
Ophthalmology Sys. Review
Narrative review identifies emerging associations between gut microbiota and pediatric eye conditions Early gut bugs may shape your child's eye health for life
This narrative review examines associations between gut microbiota dysbiosis and pediatric ophthalmic conditions including myopia and allerg…
New research suggests that the tiny bugs living in a child's gut could be the hidden reason behind their eye problems.
Frontiers Apr 28, 2026
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery
Allergy & Immunology FDA Approval
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery FDA approves Dupixent for treating allergic fungal sinus infections in patients who have had sinus surgery
Dupixent (dupilumab) has been approved for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosi…
FDA approves Dupixent for allergic fungal sinus infections in adults and children aged 6 and older who have had sinus surgery.
FDA Apr 21, 2026